

# Karl Swedberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5438586/publications.pdf>

Version: 2024-02-01

264  
papers

48,263  
citations

4960

84  
h-index

1634

215  
g-index

273  
all docs

273  
docs citations

273  
times ranked

24416  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in <scp>EMPHASIS&CHF</scp> and <scp>RALES</scp>. European Journal of Heart Failure, 2022, 24, 529-538.	7.1	7
2	Effect of sacubitril/valsartan on investigator&#x2013;reported ventricular arrhythmias in <scp>PARADIGM&CHF</scp>. European Journal of Heart Failure, 2022, 24, 551-561.	7.1	20
3	<scp>Angiotensin&#x2013;nepirylsin</scp> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure, 2022, 24, 1591-1598.	7.1	14
4	Effects of a Person-Centered eHealth Intervention for Patients on Sick Leave Due to Common Mental Disorders (PROMISE Study): Open Randomized Controlled Trial. JMIR Mental Health, 2022, 9, e30966.	3.3	6
5	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clinical Research in Cardiology, 2021, 110, 1234-1248.	3.3	8
6	Effects of person&#x2013;centred care via telephone on self&#x2013;efficacy in patients with chronic obstructive pulmonary disease: Subgroup analysis of a randomized controlled trial. Nursing Open, 2021, 8, 927-935.	2.4	10
7	Implementation of Person-Centered Care: A Feasibility Study Using the WE-CARE Roadmap. International Journal of Environmental Research and Public Health, 2021, 18, 2205.	2.6	9
8	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM&#x2013;HF. Journal of the American Heart Association, 2021, 10, e019238.	3.7	20
9	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. Circulation: Heart Failure, 2021, 14, e008052.	3.9	13
10	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a <scp>PARADIGM&CHF</scp> analysis. European Journal of Heart Failure, 2021, 23, 1346-1356.	7.1	11
11	Incidence and Outcomes of Pneumonia in Patients With Heart&#x2013;Failure. Journal of the American College of Cardiology, 2021, 77, 1961-1973.	2.8	35
12	Heart failure subtypes: Pathophysiology and definitions. Diabetes Research and Clinical Practice, 2021, 175, 108815.	2.8	9
13	Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. Clinical Research in Cardiology, 2021, 110, 1308-1320.	3.3	3
14	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. Circulation: Heart Failure, 2021, 14, e008075.	3.9	3
15	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the <scp>PARADIGM&CHF</scp> trial. European Journal of Heart Failure, 2021, 23, 1518-1524.	7.1	20
16	Testing cost containment of future healthcare with maintained or improved quality&#x2013;The <scp>COSTCARES</scp> project. Health Science Reports, 2021, 4, e309.	1.5	9
17	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HF&#x2013;rEF from PARADIGM-HF and ATMOSPHERE. Clinical Research in Cardiology, 2021, 110, 1334-1349.	3.3	4
18	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. American Heart Journal, 2021, 237, 45-53.	2.7	3

#	ARTICLE	IF	CITATIONS
19	The clinical practice of treating patients with chronic heart failure needs to be improved. <i>European Journal of Heart Failure</i> , 2021, 23, 1512-1513.	7.1	1
20	Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF. <i>Clinical Research in Cardiology</i> , 2021, 111, 440.	3.3	4
21	Effects of Person-Centered Care Using a Digital Platform and Structured Telephone Support for People With Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2021, 23, e26794.	4.3	13
22	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020, 141, 352-361.	1.6	335
23	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 528-538.	7.1	28
24	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. <i>JACC: Heart Failure</i> , 2020, 8, 844-855.	4.1	56
25	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. <i>ESC Heart Failure</i> , 2020, 7, 3355-3364.	3.1	9
26	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020, 22, 2370-2379.	7.1	14
27	Person-centred care by a combined digital platform and structured telephone support for people with chronic obstructive pulmonary disease and/or chronic heart failure: study protocol for the PROTECT randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e036356.	1.9	11
28	Person-centred eHealth intervention for patients on sick leave due to common mental disorders: study protocol of a randomised controlled trial and process evaluation (PROMISE). <i>BMJ Open</i> , 2020, 10, e037515.	1.9	7
29	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006541.	3.9	96
30	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 432.	6.1	59
31	The prevalence and importance of frailty in heart failure with reduced ejection fraction—An analysis of <sc>PARADIGM-HF</sc> and <sc>ATMOSPHERE</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 2123-2133.	7.1	85
32	The Evolution of $\beta$ -Blockers in Coronary Artery Disease and Heart Failure (Part 1/5). <i>Journal of the American College of Cardiology</i> , 2019, 74, 672-682.	2.8	44
33	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 601-612.	2.8	97
34	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 974-984.	7.1	52
35	Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.. <i>ESC Heart Failure</i> , 2019, 6, 1199-1207.	3.1	11
36	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2019, 140, 1369-1379.	1.6	74

#	ARTICLE	IF	CITATIONS
37	Outcomes and Effect of Treatment According to Etiology in HFrEF. <i>JACC: Heart Failure</i> , 2019, 7, 457-465.	4.1	94
38	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 418-427.	4.1	20
39	A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	7.1	264
40	Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial. <i>Pharmacoeconomics - Open</i> , 2019, 3, 495-504.	1.8	23
41	Income Inequality and Outcomes in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 336-346.	4.1	63
42	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 337-341.	7.1	129
43	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 345-351.	7.1	43
44	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006539.	3.9	78
45	Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. <i>Clinical Research in Cardiology</i> , 2019, 108, 806-814.	3.3	5
46	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , 2019, 73, 29-40.	2.8	168
47	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , 2019, 21, 577-587.	7.1	38
48	The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. <i>European Journal of Heart Failure</i> , 2019, 21, 40-49.	7.1	54
49	Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2018, 3, 498.	6.1	84
50	Renal Effects and Associated Outcomes During Angiotensin-Nepriylsin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 489-498.	4.1	272
51	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. <i>Circulation: Heart Failure</i> , 2018, 11, e004745.	3.9	55
52	Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure). <i>Circulation: Heart Failure</i> , 2018, 11, e004431.	3.9	13
53	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2018, 20, 760-768.	7.1	62
54	The year in cardiology 2017: heart failure. <i>European Heart Journal</i> , 2018, 39, 832-839.	2.2	5

#	ARTICLE	IF	CITATIONS
55	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. JACC: Heart Failure, 2018, 6, 564-569.	4.1	43
56	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. European Journal of Heart Failure, 2018, 20, 268-277.	7.1	42
57	Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure, 2018, 20, 373-381.	7.1	41
58	Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. European Journal of Heart Failure, 2018, 20, 295-303.	7.1	65
59	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. European Journal of Heart Failure, 2018, 20, 514-522.	7.1	35
60	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. European Journal of Heart Failure, 2018, 20, 504-510.	7.1	52
61	Lessons for the monitoring of safety in clinical trials. European Journal of Heart Failure, 2018, 20, 148-148.	7.1	2
62	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Nephrilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2018, 3, 1226.	6.1	38
63	Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy <i>Comment on:</i> "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi <i>et al.</i>. ESC Heart Failure, 2018, 5, 1069-1071.	3.1	15
64	Effects of a person-centred telephone-support in patients with chronic obstructive pulmonary disease and/or chronic heart failure "A randomized controlled trial. PLoS ONE, 2018, 13, e0203031.	2.5	58
65	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	6
66	Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. European Journal of Heart Failure, 2018, 20, 1315-1322.	7.1	96
67	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. European Heart Journal, 2017, 38, ehw509.	2.2	36
68	Comments on meta-analysis of ivabradine as adjuvant treatment for chronic heart failure by Mizzaci et al.. International Journal of Cardiology, 2017, 239, 2.	1.7	0
69	Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases. European Journal of Heart Failure, 2017, 19, 449-456.	7.1	19
70	Editorial commentary: Guidelines for the treatment of chronic heart failure. Trends in Cardiovascular Medicine, 2017, 27, 324-325.	4.9	1
71	Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 317-326.	4.1	91
72	Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 399-407.	4.1	31

#	ARTICLE	IF	CITATIONS
73	Achieving a Maximally Tolerated $\beta$ -Blocker Dose in Heart Failure Patients. Journal of the American College of Cardiology, 2017, 69, 2542-2550.	2.8	41
74	Heart rate and its reduction in chronic heart failure and beyond. European Journal of Heart Failure, 2017, 19, 1230-1241.	7.1	37
75	Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. Journal of the American College of Cardiology, 2017, 69, 2606-2618.	2.8	79
76	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 2017, 38, 1132-1143.	2.2	160
77	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. European Journal of Heart Failure, 2017, 19, 718-727.	7.1	17
78	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. European Journal of Heart Failure, 2017, 19, 1186-1197.	7.1	75
79	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. American Heart Journal, 2017, 188, 35-41.	2.7	32
80	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes and Endocrinology, 2017, 5, 333-340.	11.4	258
81	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovascular Drugs and Therapy, 2017, 31, 545-549.	2.6	55
82	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circulation: Heart Failure, 2017, 10, .	3.9	53
83	Effects of person-centred care after an event of acute coronary syndrome: Two-year follow-up of a randomised controlled trial. International Journal of Cardiology, 2017, 249, 42-47.	1.7	36
84	Health-Related Quality of Life Outcomes in PARADIGM-HF. Circulation: Heart Failure, 2017, 10, .	3.9	150
85	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	3.9	53
86	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2017, 70, 2490-2500.	2.8	114
87	Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51.	27.0	355
88	Can beta-blockers be used safely in non-cardiac surgery? Important lessons to be learned. European Heart Journal, 2017, 38, 2429-2430.	2.2	1
89	Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris. Cardiology, 2017, 136, 138-144.	1.4	15
90	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. JAMA Cardiology, 2017, 2, 79.	6.1	143

#	ARTICLE	IF	CITATIONS
91	Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 129-137.	7.1	95
92	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 241-249.	7.1	22
93	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2016, 18, 672-683.	7.1	21
94	Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the <i>Angiotensin Receptor Inhibitor Ivabradine Trial (SHIFT) Trial</i> . <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	20
95	Challenges to Data Monitoring Committees When Regulatory Authorities Intervene. <i>New England Journal of Medicine</i> , 2016, 374, 1580-1584.	27.0	17
96	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. <i>Circulation</i> , 2016, 133, 2254-2262.	1.6	142
97	Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of PARADIGM-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 1182-1189.	7.1	39
98	Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2016, 134, 1785-1787.	1.6	35
99	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Therapy). <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	83
100	Effectiveness of person-centred care after acute coronary syndrome in relation to educational level: Subgroup analysis of a two-armed randomised controlled trial. <i>International Journal of Cardiology</i> , 2016, 221, 957-962.	1.7	41
101	Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. <i>Journal of the American College of Cardiology</i> , 2016, 68, 241-248.	2.8	101
102	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF). <i>Circulation</i> , 2016, 134, 1785-1787.	1.6	35
103	Editorial Commentary: The success of heart rate control in the treatment of chronic heart failure. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 450-451.	4.9	0
104	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	52
105	Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. <i>European Journal of Heart Failure</i> , 2016, 18, 1175-1181.	7.1	12
106	Risk Related to Pre-diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	260
107	Optimizing the Management of Heart Failure With Preserved Ejection Fraction in the Elderly by Targeting Comorbidities (OPTIMIZE-HFPEF). <i>Journal of Cardiac Failure</i> , 2016, 22, 539-544.	1.7	25
108	Health-care improvements in a financially constrained environment. <i>Lancet</i> , 2016, 387, 646-647.	13.7	20

#	ARTICLE	IF	CITATIONS
109	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the Tj ETQq1 1 0.784314 rgBT/Overlo	1.6	15
110	Treatment of diabetes and heart failure: joint forces. <i>European Heart Journal</i> , 2016, 37, 1535.2-1537.	2.2	12
111	From CONSENSUS to SAVE: The Early Development of Inhibition of the Renin-Angiotensin System in the Treatment of Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 395-398.	1.7	7
112	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002744.	3.9	130
113	Influenza Vaccination in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 152-158.	4.1	112
114	Person-centred care for patients with chronic heart failure – a cost-utility analysis. <i>European Journal of Cardiovascular Nursing</i> , 2016, 15, 276-284.	0.9	71
115	An eHealth Diary and Symptom-Tracking Tool Combined With Person-Centered Care for Improving Self-Efficacy After a Diagnosis of Acute Coronary Syndrome: A Substudy of a Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2016, 18, e40.	4.3	64
116	Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015, 17, 1201-1207.	7.1	35
117	Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1294-1301.	7.1	58
118	Commentary: Swedish initiative on person centred care. <i>BMJ</i> , The, 2015, 350, h160.	6.0	65
119	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1022-1031.	7.1	52
120	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , 2015, 36, 1106-1114.	2.2	53
121	Effect of Combining Ivabradine and $\beta$ -Blockers: Focus on the Use of Carvedilol in the SHIFT Population. <i>Cardiology</i> , 2015, 131, 218-224.	1.4	25
122	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. <i>European Heart Journal</i> , 2015, 36, 1990-1997.	2.2	335
123	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2015, 115, 790-796.	1.6	37
124	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. <i>Circulation</i> , 2015, 131, 54-61.	1.6	552
125	Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model. <i>International Journal of Cardiology</i> , 2015, 184, 163-169.	1.7	38
126	Mixed results for heart failure therapies. <i>Nature Reviews Cardiology</i> , 2015, 12, 73-75.	13.7	3



#	ARTICLE	IF	CITATIONS
127	Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1282-1292.	1.7	10
128	Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction. <i>American Journal of Medicine</i> , 2015, 128, 1102-1108.e6.	1.5	24
129	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2015, 36, 2310-2317.	2.2	30
130	Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. <i>European Journal of Heart Failure</i> , 2015, 17, 518-526.	7.1	54
131	Person-centred care after acute coronary syndrome, from hospital to primary care – A randomised controlled trial. <i>International Journal of Cardiology</i> , 2015, 187, 693-699.	1.7	114
132	Effect of Ivabradine on Early Readmissions After Hospitalization for Worsening Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 268-269.	4.1	3
133	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2059-2071.	2.8	118
134	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. <i>European Heart Journal</i> , 2015, 36, 2576-2584.	2.2	187
135	Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). <i>American Journal of Cardiology</i> , 2015, 116, 1890-1897.	1.6	54
136	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation</i> , 2015, 131, 43-53.	1.6	75
137	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , 2015, 36, 669-675.	2.2	62
138	Abstract 18395: Safety of Continuing Ivabradine Treatment During Hospitalization for Worsening of Heart Failure in the SHIFT Study. <i>Circulation</i> , 2015, 132, .	1.6	0
139	Relaxing from dyspnoea. <i>European Heart Journal</i> , 2014, 35, 1017-1018.	2.2	0
140	Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. <i>European Journal of Heart Failure</i> , 2014, 16, 810-816.	7.1	58
141	Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. <i>European Journal of Heart Failure</i> , 2014, 16, 76-85.	7.1	70
142	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2014, 16, 426-434.	7.1	42
143	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM – Preserved. <i>European Journal of Heart Failure</i> , 2014, 16, 33-40.	7.1	186
144	Disease-specific health status as a predictor of mortality. <i>European Journal of Heart Failure</i> , 2014, 16, 923-923.	7.1	0

#	ARTICLE	IF	CITATIONS
145	Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 895-902.	3.9	43
146	Efficacy and Safety of Ivabradine in Patients With Severe Chronic Systolic Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50	1.6	45
147	Baseline characteristics and treatment of patients in Prospective comparison of <sc>ARNI</sc> with <sc>ACEI</sc> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<sc>PARADIGMâ€HF</sc>). <i>European Journal of Heart Failure</i> , 2014, 16, 817-825.	7.1	148
148	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	3.9	34
149	Angiotensinâ€Nepirylsin Inhibition versus Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2014, 371, 993-1004.	27.0	5,052
150	The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. <i>European Heart Journal</i> , 2014, 35, 2001-2009.	2.2	274
151	Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 590-595.	3.9	123
152	Abstract 12794: Hospital Length of Stay and Readmissions Post Heart Failure Hospitalization in the EVEREST Trial. <i>Circulation</i> , 2014, 130, .	1.6	1
153	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensinâ€converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). <i>European Journal of Heart Failure</i> , 2013, 15, 1062-1073.	7.1	358
154	Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1585-1593.	2.8	204
155	Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1977-1985.	2.8	104
156	Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 79-84.	7.1	24
157	Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. <i>European Journal of Heart Failure</i> , 2013, 15, 1296-1303.	7.1	63
158	Risk following hospitalization in stable chronic systolic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 885-891.	7.1	42
159	The past, present and future of reninâ€angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687.	1.7	97
160	Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. <i>Clinical Research in Cardiology</i> , 2013, 102, 11-22.	3.3	199
161	The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. <i>JACC: Heart Failure</i> , 2013, 1, 488-496.	4.1	58
162	Efficacy of personâ€centred care as an intervention in controlled trials â€ a systematic review. <i>Journal of Clinical Nursing</i> , 2013, 22, 456-465.	3.0	215

#	ARTICLE	IF	CITATIONS
163	Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2013, 368, 1210-1219.	27.0	462
164	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. <i>European Heart Journal</i> , 2013, 34, 2263-2270.	2.2	85
165	Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. <i>European Heart Journal</i> , 2013, 34, 1404-1413.	2.2	921
166	Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy. <i>Circulation: Heart Failure</i> , 2013, 6, 711-718.	3.9	35
167	Uncertainty in illness among patients with chronic heart failure is less in person-centred care than in usual care. <i>European Journal of Cardiovascular Nursing</i> , 2013, 12, 521-528.	0.9	77
168	The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2013, 34, 2823-2829.	2.2	79
169	Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (REDâ€œHF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	7.1	24
170	Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 1044-1052.	7.1	22
171	Effects of person-centred care in patients with chronic heart failure: the PCC-HF study. <i>European Heart Journal</i> , 2012, 33, 1112-1119.	2.2	261
172	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012, 33, 2782-2795.	2.2	148
173	Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. <i>European Heart Journal</i> , 2012, 33, 2813-2820.	2.2	126
174	The beat goes on: on the importance of heart rate in chronic heart failure. <i>European Heart Journal</i> , 2012, 33, 1044-1045.	2.2	7
175	The Impact of Chronic Obstructive Pulmonary Disease in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction: An Analysis of the EVEREST Trial. <i>Journal of Cardiac Failure</i> , 2012, 18, 515-523.	1.7	62
176	Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1598-1603.	2.8	249
177	Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1785-1795.	2.8	146
178	Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1938-1945.	2.8	233
179	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. <i>New England Journal of Medicine</i> , 2011, 364, 11-21.	27.0	2,491
180	Optimal Pharmacological Therapy in Chronic Heart Failure 2011 - How to Achieve the Standard. <i>Journal of Cardiac Failure</i> , 2011, 17, S123-S124.	1.7	0

#	ARTICLE	IF	CITATIONS
181	Heart rate reduction in cardiovascular disease and therapy. <i>Clinical Research in Cardiology</i> , 2011, 100, 11-19.	3.3	95
182	nâ€“3 Fatty Acids in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2011, 365, 1159-1159.	27.0	5
183	Measuring shortness of breath in heart failure (SOBâ€“HF): development and validation of a new dyspnoea assessment tool. <i>European Journal of Heart Failure</i> , 2011, 13, 838-845.	7.1	16
184	Impact of deviceâ€“guided slow breathing on symptoms of chronic heart failure: a randomized, controlled feasibility study. <i>European Journal of Heart Failure</i> , 2011, 13, 1000-1005.	7.1	24
185	Person-Centered Care â€” Ready for Prime Time. <i>European Journal of Cardiovascular Nursing</i> , 2011, 10, 248-251.	0.9	1,151
186	Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. <i>European Heart Journal</i> , 2011, 32, 2395-2404.	2.2	175
187	Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. <i>European Heart Journal</i> , 2011, 32, 2507-2515.	2.2	264
188	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet, The</i> , 2010, 376, 875-885.	13.7	2,119
189	Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NTâ€“proBNP Guided Management of Heart Failure â€” SIGNALâ€“HF (Swedish Intervention study â€“ Guidelines) Tj ETIQq1 1 0 2784314	7.1	88
190	Rationale and design of a randomized, doubleâ€“blind, placeboâ€“controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I<sub>f</sub>/sub> Inhibitor Ivabradine Trial (SHIFT). <i>European Journal of Heart Failure</i> , 2010, 12, 75-81.	7.1	88
191	Thoughts from an outgoing Editor-in-Chief. <i>European Journal of Heart Failure</i> , 2010, 12, 3-3.	7.1	3
192	Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure - a COMET substudy. <i>Thrombosis Research</i> , 2010, 125, e46-e50.	1.7	7
193	Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. <i>Lancet, The</i> , 2010, 376, 886-894.	13.7	769
194	Rationale and design of the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASISâ€“HF). <i>European Journal of Heart Failure</i> , 2010, 12, 617-622.	7.1	66
195	What should we do about heart failure: challenges for 2009. <i>European Journal of Heart Failure</i> , 2009, 11, 1-2.	7.1	0
196	Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden. <i>European Journal of Heart Failure</i> , 2009, 11, 92-98.	7.1	61
197	Reviewers 2008. <i>European Journal of Heart Failure</i> , 2009, 11, 225-226.	7.1	1
198	Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 of Heart Failure, 2009, 11, 1143-1151.	7.1	118

#	ARTICLE	IF	CITATIONS
199	Fallacies in clinical cardiovascular trials. <i>Heart</i> , 2009, 95, 1464-1468.	2.9	2
200	QRS Amplitudes, QTc Intervals and ECG Abnormalities in Pheochromocytoma Patients before, during and after Treatment. <i>Acta Medica Scandinavica</i> , 2009, 224, 231-235.	0.0	24
201	Plasma Concentrations of Platelet Factor 4 in Acute Myocardial Infarction. <i>Scandinavian Journal of Haematology</i> , 2009, 26, 359-363.	0.0	3
202	Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2009, 11, 292-298.	7.1	102
203	Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1640-1648.	2.8	159
204	How to publish in <i>European Journal of Heart Failure</i> – what do we want?. <i>European Journal of Heart Failure</i> , 2008, 10, 1-2.	7.1	2
205	Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. <i>European Heart Journal</i> , 2008, 30, 671-678.	2.2	92
206	Successful treatment of heart failure with devices requires collaboration. <i>European Journal of Heart Failure</i> , 2008, 10, 1229-1235.	7.1	29
207	Response to Letter Regarding Article, “Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure”, <i>Circulation</i> , 2008, 118, .	1.6	1
208	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008, 29, 1377-1385.	2.2	549
209	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. <i>European Journal of Heart Failure</i> , 2008, 10, 933-989.	7.1	1,893
210	Who is an author?. <i>European Journal of Heart Failure</i> , 2008, 10, 523-524.	7.1	6
211	Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial. <i>European Journal of Heart Failure</i> , 2007, 9, 795-801.	7.1	69
212	Pure heart rate reduction: further perspectives in heart failure. <i>Country Review Ukraine</i> , 2007, 9, F20-F24.	0.8	9
213	Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 1482-1487.	1.6	528
214	Awaiting publication - A frustrating period for the scientist and the editor. <i>European Journal of Heart Failure</i> , 2007, 9, 547-547.	7.1	1
215	Another year with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 1-1.	7.1	4
216	Reviewers 2006. <i>European Journal of Heart Failure</i> , 2007, 9, 109-109.	7.1	0

#	ARTICLE	IF	CITATIONS
217	Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1997-2004.	2.8	507
218	Diagnostic and Therapeutic Algorithms in Chronic Heart Failure. <i>Herz</i> , 2006, 31, 877-880.	1.1	2
219	Treatment of chronic heart failure: a comparison between the major guidelines. <i>European Heart Journal</i> , 2006, 27, 1773-1777.	2.2	46
220	Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients. <i>Circulation</i> , 2005, 112, 3738-3744.	1.6	678
221	1446 Assessing Dyspnoea in Patients with Chronic Heart Failure—Does Gender Make a Difference?. <i>European Journal of Cardiovascular Nursing</i> , 2005, 4, 65-66.	0.9	0
222	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). <i>European Heart Journal</i> , 2005, 26, 1115-1140.	2.2	1,986
223	Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. <i>European Heart Journal</i> , 2005, 26, 1303-1308.	2.2	564
224	Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. <i>European Heart Journal</i> , 2005, 26, 2706-2713.	2.2	172
225	Symptoms in Patients With Heart Failure are Prognostic Predictors: Insights From COMET. <i>Journal of Cardiac Failure</i> , 2005, 11, 288-292.	1.7	168
226	Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. <i>European Heart Journal</i> , 2005, 26, 2259-2268.	2.2	154
227	Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET. <i>American Heart Journal</i> , 2005, 149, 370-376.	2.7	74
228	Conclusions on the management of heart failure.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, S34.	1.7	0
229	Decreasing one-year mortality and hospitalization rates for heart failure in Sweden Data from the Swedish Hospital Discharge Registry 1988 to 2000. <i>European Heart Journal</i> , 2004, 25, 300-307.	2.2	234
230	Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. <i>Circulation</i> , 2004, 110, 2618-2626.	1.6	347
231	Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. <i>New England Journal of Medicine</i> , 2003, 349, 1893-1906.	27.0	2,240
232	Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. <i>Lancet</i> , The, 2003, 362, 7-13.	13.7	1,664
233	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet</i> , The, 2003, 362, 759-766.	13.7	1,752
234	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. <i>Lancet</i> , The, 2003, 362, 767-771.	13.7	1,978

#	ARTICLE	IF	CITATIONS
235	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. <i>Lancet, The</i> , 2003, 362, 772-776.	13.7	1,623
236	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. <i>Lancet, The</i> , 2003, 362, 777-781.	13.7	2,584
237	β <sub>2</sub> -Blockers in Chronic Heart Failure. <i>Circulation</i> , 2003, 107, 1570-1575.	1.6	150
238	Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart Failure. <i>Circulation</i> , 2002, 105, 1797-1803.	1.6	95
239	Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. <i>European Journal of Heart Failure</i> , 2002, 4, 321-329.	7.1	69
240	Skeletal muscle characteristics, muscle strength and thigh muscle area in patients before and after cardiac transplantation. <i>European Journal of Heart Failure</i> , 2001, 3, 59-67.	7.1	60
241	Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 35-43.	2.4	14
242	ST Variability during the First 4 Hours of Acute Myocardial Infarction Predicts 1-Year Mortality. <i>Annals of Noninvasive Electrocardiology</i> , 2001, 6, 198-202.	1.1	11
243	Implantable left ventricular assist systems (LVAS): Recent results. A report from a series of meetings sponsored by the Study Group on Advanced Heart Failure of the Working Group on Heart Failure. <i>European Journal of Heart Failure</i> , 2000, 2, 13-18.	7.1	6
244	Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. <i>European Journal of Heart Failure</i> , 2000, 2, 229-233.	7.1	30
245	Exploring New Treatment Strategies in Heart Failure. <i>Blood Pressure</i> , 2000, 9, 44-48.	1.5	2
246	Effects of the I <sub>kr</sub> -blocker almokalant and predictors of conversion of chronic atrial tachyarrhythmias to sinus rhythm. A prospective study. <i>Cardiovascular Drugs and Therapy</i> , 1999, 13, 329-338.	2.6	8
247	Electrocardiographic and Clinical Predictors of Torsades de Pointes Induced by Almokalant Infusion in Patients with Chronic Atrial Fibrillation or Flutter: A Prospective Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998, 21, 1044-1057.	1.2	105
248	Acute Myocardial Infarction: Difference in the Treatment between Men and Women. <i>International Journal for Quality in Health Care</i> , 1993, 5, 261-265.	1.8	34
249	Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative) Tj ETQq1 1 0.784314 rgBT /Overload 1992, 70, 479-487.	1.6	176
250	The effect of treatment on survival in congestive heart failure. <i>Clinical Cardiology</i> , 1992, 15, 323-329.	1.8	11
251	Effect of Enalapril on Mortality in Congestive Heart Failure. <i>Drugs</i> , 1990, 39, 49-52.	10.9	22
252	Effects on Mortality during Five Years after Early Intervention with Metoprolol in Suspected Acute Myocardial Infarction. <i>Acta Medica Scandinavica</i> , 1988, 223, 227-231.	0.0	12

#	ARTICLE	IF	CITATIONS
253	Use of Nitrates in Acute and Chronic Congestive Heart Failure. <i>Drugs</i> , 1987, 33, 147-149.	10.9	4
254	Self-assessment of quality of life in severe heart failure: An instrument for clinical use. <i>Scandinavian Journal of Psychology</i> , 1987, 28, 220-225.	1.5	105
255	Assessment of Quality of Life in Clinical Trials. <i>Acta Medica Scandinavica</i> , 1986, 220, 1-3.	0.0	13
256	EFFECTS OF ACE-INHIBITION ON REGIONAL CIRCULATION IN CONGESTIVE HEART FAILURE. <i>Acta Medica Scandinavica</i> , 1986, 219, 91-93.	0.0	4
257	Development of tolerance to nitrate therapy in chronic congestive heart failure. <i>Acta Pharmacologica Et Toxicologica</i> , 1986, 59, 49-51.	0.0	0
258	ADP-induced Platelet Aggregation and Metoprolol Treatment of Myocardial Infarction Patients. <i>Acta Medica Scandinavica</i> , 1985, 217, 15-20.	0.0	8
259	Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. <i>American Journal of Cardiology</i> , 1984, 54, 783-786.	1.6	179
260	Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure: Acute and chronic hemodynamic evaluations. <i>Journal of the American College of Cardiology</i> , 1983, 2, 865-871.	2.8	107
261	Possible adrenergic effects on heart protein metabolism. <i>Acta Medica Scandinavica</i> , 1983, 213, 85-93.	0.0	4
262	Plasma Levels of Platelet Factor 4 in Patients Admitted to a Coronary Care Unit. <i>Scandinavian Journal of Haematology</i> , 1981, 26, 235-240.	0.0	9
263	PROLONGATION OF SURVIVAL IN CONGESTIVE CARDIOMYOPATHY BY BETA-RECEPTOR BLOCKADE. <i>Lancet</i> , The, 1979, 313, 1374-1376.	13.7	377
264	Hemodynamic Effects of the Cardioselective $\beta_1$ -Blocking Agent Metoprolol in Acute Myocardial Infarction. <i>Acta Medica Scandinavica</i> , 1978, 204, 195-201.	0.0	20